Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epalrestat
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
Details : Epalrestat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Congenital Disorders of Glycosylation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 14, 2021
Lead Product(s) : Epalrestat
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable